Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Not Recruiting

Trial ID: NCT03373435


This clinical study will evaluate whether taking an investigational drug called exendin 9-39 is safe, well-tolerated, and helps to prevent low blood sugar in people who have had bariatric surgery and later develop a rare condition called postbariatric hypoglycemia (PBH).

Official Title

A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Stanford Investigator(s)

Marilyn Tan
Marilyn Tan

Clinical Associate Professor, Medicine - Endocrinology, Gerontology, & Metabolism


Inclusion Criteria:

   - Body mass index (BMI) of up to 40 kg/m2

   - Roux-en-Y gastric bypass (RYGB) surgery performed ≥12 months prior

   - Diagnosis of PBH

   - At least 2 episodes during screening 2-week run-in phase of severe hypoglycemia

Exclusion Criteria:

   - Other cause of endogenous hyperinsulinism other than PBH

   - Metabolic or bariatric surgical procedure other than RYGB

   - History of non-RYGB upper GI surgery

   - Use of agents that may interfere with glucose metabolism


drug: exendin 9-39

other: Placebo

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Aileen Muno
(650) 725-9890